Clinical Trials for Clarity Pharmaceuticals

Explore 4 clinical trials worldwide

Showing 1-4 of 4 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Clarity Pharmaceuticals

Clinical Trials (4)

NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
PHASE3Recruiting
220 participants
Started: May 16, 2025 · Completed: Dec 31, 2026
6 conditions1 sponsor3 locations
NCT06907641
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
PHASE2Recruiting
50 participants
Started: Nov 21, 2024 · Completed: Nov 30, 2025
1 condition2 sponsors1 location
NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
PHASE3Recruiting
383 participants
Started: Dec 21, 2023 · Completed: Dec 31, 2025
2 conditions1 sponsor23 locations
NCT04868604
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
PHASE1/PHASE2Recruiting
54 participants
Started: Aug 11, 2021 · Completed: Sep 30, 2026
1 condition1 sponsor6 locations